NCI-2025-03571

A Phase 1, First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC028 in Participants with Advanced Solid Tumors

This is a Phase 1, First-in-Human research study for people with various advanced solid tumors (like certain lung, pancreatic, or colon cancers). MGC028 is designed to target a protein called ADAM9 that is often found on these tumors. By targeting this protein, the drug aims to disrupt the tumor's growth and help the immune system. The main goal is to find the safest dose and look at the types of side effects the new drug, MGC028, causes.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06723236

Clinical Trial Site: Sinai

To see all available clinical trials click here.